You are here

Calls for proposals

Drug available for combination trials

The Cancer Research UK's Combinations Alliance and the NIHR CRN Industry Alliance are collaborating to support access to novel agents

We invite researchers from both the ECMC and NIHR networks to submit novel proposals involving the novel drug below with standard of care chemotherapy and/or radiotherapy and/or another novel drug. An overview of the benefits, expectations and framework for resarchers can be found on the researchers page with the details of this call below.

Applications will be prioritised based on scientific and clinical merit, alignment with CRUK's Statement of Intent and fit with the core development program of the drug.

Next call open - TBA
Mode of Action Drug Company Webinar date Primary contact

 

 

 

   
How to apply
  1. Review the drug on offer by reading the <data pack> and consider a novel proposal involving another drug, chemotherapy or radiotherapy 
  2. Read the guidelines
  3. Attend the webinar by contacting CombinationsAlliance@cancer.org.uk
  4. Submit the non-confidential EOI form to CombinationsAlliance@cancer.org.uk

EOIs are reviewed in a two-stage process; closed review followed by face-to-face workshop and successful applicants will apply via CRUK’s Clinical Research Committee CRC

Trial open expectation is within 12 months of CRC meeting. 

Key dates

Webinar

 

EOI submission deadline  
EOI Feedback  
F2F workshop for invited applicants  
Workshop feedback  
CRC submission deadline > 500k

Primary: 19 March 2019

Secondary: July 2019

CRC submission deadline < 500k  Early June 2019
CRC meeting  Nov 2019
Trial open   Nov 2020 

 

About ECMC Combinations Alliance EOI calls

EOI calls are made twice a year, dependent on partner offerings, via the ECMC network. Our formal EOI calls are driven by the Clinical Research Committee Meeting schedule via the Clinical Trial Awards

Early phase combination proposals involving the offered novel drug with either another novel drug, chemotherapy or radiotherapy are welcome and will be prioritised based on scientific and clinical merit and fit with the core development program of the drug. 

Have an idea that doesn’t fit with the drug available?  

EOIs submitted outside of these formal EOI calls are welcomed and reviewed on an ad hoc basis. We encourage you to contact us with your novel combination ideas outside the formal rounds and if you would like to be added to the direct ECMC distribution list please email us your request.